Bayesian Networks to Support Decision-Making for Immune-Checkpoint Blockade in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

Cancers

Matthaeus Stoehr¹  Marius Huehn¹  Andreas Dietz¹  Gunnar Wichmann¹  Jan Gaebel²  Alexander Oeser²  Thomas Neumuth² 

[1] Head and Neck Surgery, Department of Otorhinolaryngology, University Hospital Leipzig, 04103 Leipzig, Germany;Innovation Center Computer Assisted Surgery (ICCAS), Faculty of Medicine, University Leipzig, 04103 Leipzig, Germany;

关键词: head and neck squamous cell carcinoma (HNSCC);    immunotherapy;    immune checkpoint blockade (ICB) targeted therapy;    Bayesian network;    molecular tumor board;    multidisciplinary tumor board;   

DOI  :  10.3390/cancers13235890

来源: DOAJ

【 摘 要 】

New diagnostic methods and novel therapeutic agents spawn additional and heterogeneous information, leading to an increasingly complex decision-making process for optimal treatment of cancer. A great amount of information is collected in organ-specific multidisciplinary tumor boards (MDTBs). By considering the patient’s tumor properties, molecular pathological test results, and comorbidities, the MDTB has to consent an evidence-based treatment decision. Immunotherapies are increasingly important in today’s cancer treatment, resulting in detailed information that influences the decision-making process. Clinical decision support systems can facilitate a better understanding via processing of multiple datasets of oncological cases and molecular genetic information, potentially fostering transparency and comprehensibility of available information, eventually leading to an optimum treatment decision for the individual patient. We constructed a digital patient model based on Bayesian networks to combine the relevant patient-specific and molecular data with depended probabilities derived from pertinent studies and clinical guidelines to calculate treatment decisions in head and neck squamous cell carcinoma (HNSCC). In a validation analysis, the model can provide guidance within the growing subject of immunotherapy in HNSCC and, based on its ability to calculate reliable probabilities, facilitates estimation of suitable therapy options. We compared actual treatment decisions of 25 patients with the calculated recommendations of our model and found significant concordance (Cohen’s κ = 0.505, p = 0.009) and 84% accuracy.

【 授权许可】

Unknown